ADAR silent treatment could bypass the typical resistance of small-molecule anticancer drugs against the immune checkpoint blockade (ICB), such as the PD-1 checkpoint blockade, in tumor molecules together with PKR and MDA5 activation, thus resulting in tumor cell growth inhibition and inflammation [59,159,160,161]. Here, ADAR is linked to neoplasm.